Hata Reo, Kubo Shunsuke, Tsuneyoshi Hiroshi, Shimamoto Takeshi, Kuwayama Akimune, Ohya Masanobu, Shimada Takenobu, Miura Katsuya, Amano Hidewo, Otsuru Suguru, Habara Seiji, Tada Takeshi, Tanaka Hiroyuki, Fuku Yasushi, Goto Tsuyoshi, Komiya Tatsuhiko, Kadota Kazushige
Department of Cardiology, Kurashiki Central Hospital, 1-1-1, Miwa, Kurashiki, Okayama, 710-8602, Japan.
Department of Cardiovascular Surgery, Kurashiki Central Hospital, 1-1-1, Miwa, Kurashiki, Okayama, 710-8602, Japan.
Cardiovasc Interv Ther. 2020 Apr;35(2):194-202. doi: 10.1007/s12928-019-00599-5. Epub 2019 Jul 10.
Studies on the outcomes of de novo three-vessel coronary artery disease (3VD) are limited. This study evaluated the outcomes after coronary revascularization in patients with 3VD treated by percutaneous coronary intervention (PCI) using second-generation drug-eluting stents (2ndDES) in comparison with coronary artery bypass grafting (CABG). We analyzed 853 patients undergoing either PCI or CABG for 3VD between 2010 and 2014. Of them, this study included 298 undergoing PCI with 2ndDES alone (PCI group) and 171 undergoing CABG (CABG group). The primary outcome measure was a composite of all-cause death, non-fatal myocardial infarction (MI), or stroke. The secondary outcome measures were cardiac death, MI, stroke, and target vessel revascularization (TVR). Propensity matching was used to adjust a cohort of patients with similar baseline characteristics. Between the PCI and CABG groups, no significant differences were found in the 3-year cumulative incidence of the primary outcome measure (14.9% vs. 12.9%, p = 0.60). After propensity score matching, no significant differences were found in the incidences of primary outcome measure (13.0% vs. 12.8%, p = 0.95), cardiac death, MI, and stroke (3.5% vs. 2.7%, p = 0.72; 1.2% vs. 0.0%, p = 0.31; and 4.9% vs. 3.1%, p = 0.35), whereas that of TVR was significantly higher in the PCI group (24.5 vs. 7.1%, p < 0.01). Compared with CABG, PCI with second-generation DES was not associated with higher risk of clinical outcomes, but was associated with a higher risk of TVR in the treatment of 3VD.
关于初发三支血管冠状动脉疾病(3VD)预后的研究有限。本研究评估了使用第二代药物洗脱支架(2ndDES)经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术(CABG)治疗3VD患者冠状动脉血运重建后的预后。我们分析了2010年至2014年间853例因3VD接受PCI或CABG的患者。其中,本研究纳入了298例仅接受2ndDES PCI的患者(PCI组)和171例接受CABG的患者(CABG组)。主要结局指标是全因死亡、非致命性心肌梗死(MI)或中风的复合指标。次要结局指标是心源性死亡、MI、中风和靶血管血运重建(TVR)。采用倾向匹配法对具有相似基线特征的患者队列进行调整。在PCI组和CABG组之间,主要结局指标的3年累积发生率无显著差异(14.9%对12.9%,p = 0.60)。倾向评分匹配后,主要结局指标的发生率(13.0%对12.8%,p = 0.95)、心源性死亡、MI和中风的发生率(3.5%对2.7%,p = 0.72;1.2%对0.0%,p = 0.31;4.9%对3.1%,p = 0.35)无显著差异,而PCI组的TVR发生率显著更高(24.5%对7.1%,p < 0.01)。与CABG相比,第二代DES PCI在治疗3VD时与临床结局风险较高无关,但与TVR风险较高有关。